FDA SETS DEADLINE FOR DECISION ON SALIX DRUG

The U.S. Food and Drug Administration expects to decide whether to approve a Raleigh pharmaceutical company's bowel cleansing agent before Aug. 2. Raleigh-based Salix Pharmaceuticals said in April it had received an "approvable letter" from the federal regulatory agency and that only certain manufacturing deficiencies for its colonoscopy treatment MoviPrep needed to be corrected.
Triangle Business Journal